These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 9600496)

  • 1. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
    Lerch E; Müller UR
    J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuing venom immunotherapy: extended observations.
    Golden DB; Kwiterovich KA; Kagey-Sobotka A; Lichtenstein LM
    J Allergy Clin Immunol; 1998 Mar; 101(3):298-305. PubMed ID: 9525443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of venom immunotherapy.
    Hafner T; DuBuske L; Kosnik M
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):162-5. PubMed ID: 18320918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
    Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
    Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.
    Bonifazi F; Jutel M; Biló BM; Birnbaum J; Muller U;
    Allergy; 2005 Dec; 60(12):1459-70. PubMed ID: 16266376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of immunotherapy with venom in children with allergy to insect stings.
    Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
    N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deliberate hymenoptera sting challenge as a diagnostic tool in highly selected venom-allergic patients.
    Goldberg A; Confino-Cohen R; Mekori YA
    Ann Allergy Asthma Immunol; 1995 Jul; 75(1):30-2. PubMed ID: 7621057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of Hymenoptera venom allergy in Eastern Spain.
    Fernandez J; Soriano V; Mayorga L; Mayor M
    Clin Exp Allergy; 2005 Feb; 35(2):179-85. PubMed ID: 15725189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens.
    Carballada F; Boquete M; Núñez R; Lombardero M; de la Torre F
    J Investig Allergol Clin Immunol; 2010; 20(6):506-13. PubMed ID: 21243935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergic reactions following first insect sting exposure.
    Reisman RE; Osur SL
    Ann Allergy; 1987 Dec; 59(6):429-32. PubMed ID: 3425982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report of venom immunotherapy for a patient with large local reactions.
    Hamilton RG; Golden DB; Kagey-Sobotka A; Lichtenstein LM
    Ann Allergy Asthma Immunol; 2001 Aug; 87(2):134-7. PubMed ID: 11527245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after venom immunotherapy.
    Golden DB
    Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):337-41. PubMed ID: 20610978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
    Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
    Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment of Hymenoptera re-sting frequency: implications for decision-making in venom immunotherapy.
    von Moos S; Graf N; Johansen P; Müllner G; Kündig TM; Senti G
    Int Arch Allergy Immunol; 2013; 160(1):86-92. PubMed ID: 22948338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.